Literature DB >> 24590577

M1 muscarinic acetylcholine receptor in Alzheimer's disease.

Shangtong Jiang1, Yanfang Li, Cuilin Zhang, Yingjun Zhao, Guojun Bu, Huaxi Xu, Yun-Wu Zhang.   

Abstract

The degeneration of cholinergic neurons and cholinergic hypofunction are pathologies associated with Alzheimer's disease (AD). Muscarinic acetylcholine receptors (mAChRs) mediate acetylcholine-induced neurotransmission and five mAChR subtypes (M1-M5) have been identified. Among them, M1 mAChR is widely expressed in the central nervous system and has been implicated in many physiological and pathological brain functions. In addition, M1 mAChR is postulated to be an important therapeutic target for AD and several other neurodegenerative diseases. In this article, we review recent progress in understanding the functional involvement of M1 mAChR in AD pathology and in developing M1 mAChR agonists for AD treatment.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24590577      PMCID： PMC5562652          DOI： 10.1007/s12264-013-1406-z

Source DB:  PubMed          Journal:  Neurosci Bull        ISSN： 1995-8218            Impact factor:   5.203


  123 in total

Review 1.  Allosteric activators of muscarinic receptors as novel approaches for treatment of CNS disorders.

Authors:  Gregory J Digby; Jana K Shirey; P Jeffrey Conn
Journal:  Mol Biosyst       Date:  2010-06-25

Review 2.  Molecular biology of muscarinic acetylcholine receptors.

Authors:  J Wess
Journal:  Crit Rev Neurobiol       Date:  1996

3.  Activation of m1 muscarinic acetylcholine receptor regulates tau phosphorylation in transfected PC12 cells.

Authors:  E Sadot; D Gurwitz; J Barg; L Behar; I Ginzburg; A Fisher
Journal:  J Neurochem       Date:  1996-02       Impact factor: 5.372

4.  Identification of a family of muscarinic acetylcholine receptor genes.

Authors:  T I Bonner; N J Buckley; A C Young; M R Brann
Journal:  Science       Date:  1987-07-31       Impact factor: 47.728

5.  Muscarinic agonists reduce tau phosphorylation in non-neuronal cells via GSK-3beta inhibition and in neurons.

Authors:  O V Forlenza; J M Spink; R Dayanandan; B H Anderton; O F Olesen; S Lovestone
Journal:  J Neural Transm (Vienna)       Date:  2000       Impact factor: 3.575

Review 6.  Muscarinic acetylcholine receptors: mutant mice provide new insights for drug development.

Authors:  Jürgen Wess; Richard M Eglen; Dinesh Gautam
Journal:  Nat Rev Drug Discov       Date:  2007-09       Impact factor: 84.694

7.  Activation of protein kinase C inhibits cellular production of the amyloid beta-protein.

Authors:  A Y Hung; C Haass; R M Nitsch; W Q Qiu; M Citron; R J Wurtman; J H Growdon; D J Selkoe
Journal:  J Biol Chem       Date:  1993-11-05       Impact factor: 5.157

Review 8.  Cholinergic treatments with emphasis on m1 muscarinic agonists as potential disease-modifying agents for Alzheimer's disease.

Authors:  Abraham Fisher
Journal:  Neurotherapeutics       Date:  2008-07       Impact factor: 7.620

Review 9.  Disease-modifying therapies in Alzheimer's disease.

Authors:  Stephen Salloway; Jacobo Mintzer; Myron F Weiner; Jeffrey L Cummings
Journal:  Alzheimers Dement       Date:  2008-02-20       Impact factor: 21.566

10.  Biology and pathophysiology of the amyloid precursor protein.

Authors:  Hui Zheng; Edward H Koo
Journal:  Mol Neurodegener       Date:  2011-04-28       Impact factor: 14.195
View more
  42 in total

1.  Effects of the Methanolic Extract of Vitellaria paradoxa Stem Bark Against Scopolamine-Induced Cognitive Dysfunction and Oxidative Stress in the Rat Hippocampus.

Authors:  Harquin Simplice Foyet; Acha Emmanuel Asongalem; Eyong Kenneth Oben; Oana Cioanca; Monica Hancianu; Lucian Hritcu
Journal:  Cell Mol Neurobiol       Date:  2015-11-30       Impact factor: 5.046

Review 2.  The cholinergic system in the pathophysiology and treatment of Alzheimer's disease.

Authors:  Harald Hampel; M-Marsel Mesulam; A Claudio Cuello; Martin R Farlow; Ezio Giacobini; George T Grossberg; Ara S Khachaturian; Andrea Vergallo; Enrica Cavedo; Peter J Snyder; Zaven S Khachaturian
Journal:  Brain       Date:  2018-07-01       Impact factor: 13.501

3.  Discovery and SAR of muscarinic receptor subtype 1 (M1) allosteric activators from a molecular libraries high throughput screen. Part 1: 2,5-dibenzyl-2H-pyrazolo[4,3-c]quinolin-3(5H)-ones as positive allosteric modulators.

Authors:  Changho Han; Arindam Chatterjee; Meredith J Noetzel; Joseph D Panarese; Emery Smith; Peter Chase; Peter Hodder; Colleen Niswender; P Jeffrey Conn; Craig W Lindsley; Shaun R Stauffer
Journal:  Bioorg Med Chem Lett       Date:  2014-11-18       Impact factor: 2.823

4.  Alzheimer's disease: from molecule to clinic.

Authors:  Jian-Zhi Wang
Journal:  Neurosci Bull       Date:  2014-04       Impact factor: 5.203

5.  Molecular mechanisms of serotonergic action of the HIV-1 antiretroviral efavirenz.

Authors:  Dhwanil A Dalwadi; Seongcheol Kim; Shahnawaz M Amdani; Zhenglan Chen; Ren-Qi Huang; John A Schetz
Journal:  Pharmacol Res       Date:  2016-05-06       Impact factor: 7.658

6.  Mnemonic and behavioral effects of biperiden, an M1-selective antagonist, in the rat.

Authors:  Anna Popelíková; Štěpán Bahník; Veronika Lobellová; Jan Svoboda; Aleš Stuchlík
Journal:  Psychopharmacology (Berl)       Date:  2018-04-21       Impact factor: 4.530

7.  The effects of the selective muscarinic M3 receptor antagonist darifenacin, and of hyoscine (scopolamine), on motion sickness, skin conductance & cognitive function.

Authors:  John F Golding; Keith A Wesnes; Brian R Leaker
Journal:  Br J Clin Pharmacol       Date:  2018-04-19       Impact factor: 4.335

8.  Involvement of M1 and CB₁ receptors in the anxiogenic-like effects induced by neostigmine injected into the rat prelimbic medial prefrontal cortex.

Authors:  M V Fogaça; A G Fedoce; N C Ferreira-Junior; F S Guimarães; L B Resstel
Journal:  Psychopharmacology (Berl)       Date:  2016-02-13       Impact factor: 4.530

Review 9.  Cholinergic modulation of the hippocampal region and memory function.

Authors:  Juhee Haam; Jerrel L Yakel
Journal:  J Neurochem       Date:  2017-08       Impact factor: 5.372

Review 10.  Mitochondrial Dysfunction and Synaptic Transmission Failure in Alzheimer's Disease.

Authors:  Lan Guo; Jing Tian; Heng Du
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.